MedDataX Logo

GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

NCT ID: NCT00269087

Last Updated: 2019-02-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

122 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-28

Study Completion Date

2006-10-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times. Subjects will be given breathing tests, and will record their breathing symptoms daily on diary cards.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

NCT00269126

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE3

A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00642148

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE2

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00268216

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE3

Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT00662805

Pulmonary Disease, Chronic Obstructive
COMPLETED

A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00372112

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluticasone propionate/salmeterol combination DISKUS

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of COPD.

Exclusion Criteria

* Diagnosis of asthma or an uncontrolled medical condition or respiratory disorder other than COPD.
Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Kodaira, , Japan

Site Status

GSK Investigational Site

Kyoto, , Japan

Site Status

GSK Investigational Site

Osaka, , Japan

Site Status

GSK Investigational Site

Tokyo, , Japan

Site Status

GSK Investigational Site

, ,

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

References

Explore related publications, articles, or registry entries linked to this study.

This study has not been published in the scientific literature.

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SCO100648

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD
NCT01192191 COMPLETED PHASE3
Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD
NCT02477397 UNKNOWN PHASE3
Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT02299375 COMPLETED PHASE2
Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)
NCT05219630 COMPLETED
28-day Repeat Dose Study of GSK573719
NCT01030965 COMPLETED PHASE2
Long-term Safety Study for GSK573719 in Japanese
NCT01702363 COMPLETED PHASE3
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
NCT02573870 COMPLETED PHASE2
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837 RECRUITING PHASE1
Study of GSK961081 in Healthy Volunteer Subjects
NCT00887406 COMPLETED PHASE1
Long-term Safety Study for GSK573719/GW642444 in Japanese
NCT01376388 COMPLETED PHASE3
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
NCT01218126 COMPLETED PHASE2
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00422604 COMPLETED PHASE2
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00676052 COMPLETED PHASE2
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
NCT00950807 COMPLETED PHASE2
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
NCT00749411 COMPLETED PHASE2
A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)
NCT01978145 COMPLETED PHASE3
A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease
NCT00774761 COMPLETED PHASE2
A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)
NCT00392587 COMPLETED PHASE2
Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease
NCT00268177 COMPLETED PHASE3
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD
NCT01039675 COMPLETED PHASE2
Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease
NCT00549146 COMPLETED PHASE3
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
NCT01072149 COMPLETED PHASE3
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects
NCT00783003 COMPLETED PHASE1
Chronic Obstructive Pulmonary Disease Endpoints Study
NCT00358358 COMPLETED PHASE4
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01319019 COMPLETED PHASE2